Eli Lilly & Co Shs Cert Deposito Arg Repr 0.14285714 ShsEli Lilly & Co Shs Cert Deposito Arg Repr 0.14285714 ShsEli Lilly & Co Shs Cert Deposito Arg Repr 0.14285714 Shs

Eli Lilly & Co Shs Cert Deposito Arg Repr 0.14285714 Shs

No trades
See on Supercharts

Key facts today


Eli Lilly's weight-loss drug Zepbound now holds nearly 60% of the obesity market, outpacing Novo Nordisk's Wegovy, which had 281,725 weekly U.S. prescriptions in late July.
Eli Lilly faces a manageable near-term risk of about 4% on core profit due to U.S. tariffs and drug pricing reforms, according to a Morningstar report.
Cigna's Evernorth unit reports over 50% of clients cover weight management drugs like Eli Lilly's Zepbound, contrasting with only 15-20% of smaller employers offering similar coverage.
Analyze the impactAnalyze the impact
Market capitalization
‪710.42 B‬USD
0.25USD
‪9.41 B‬USD
‪40.01 B‬USD
Beta (1Y)
0.06

About Eli Lilly and Company


CEO
David A. Ricks
Website
Headquarters
Indianapolis
Founded
1876
ISIN
ARDEUT111192
FIGI
BBG000HFVYP1
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Check out other big names from the same industry as LLYD.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
LLY6153503
Eli Lilly and Company 5.65% 15-OCT-2065
Yield to maturity
Maturity date
Oct 15, 2065
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064
Yield to maturity
Maturity date
Aug 14, 2064
LLY4492876
Eli Lilly and Company 3.1% 15-MAY-2027
Yield to maturity
Maturity date
May 15, 2027
LLY6153506
Eli Lilly and Company 4.0% 15-OCT-2028
Yield to maturity
Maturity date
Oct 15, 2028
LLY6153507
Eli Lilly and Company 4.25% 15-MAR-2031
Yield to maturity
Maturity date
Mar 15, 2031
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063
Yield to maturity
Maturity date
Feb 27, 2063
LLY4492882
Eli Lilly and Company 3.95% 15-MAY-2047
Yield to maturity
Maturity date
May 15, 2047
LLY5750404
Eli Lilly and Company 4.5% 09-FEB-2029
Yield to maturity
Maturity date
Feb 9, 2029
LLY5871807
Eli Lilly and Company 4.6% 14-AUG-2034
Yield to maturity
Maturity date
Aug 14, 2034
LLY6153403
Eli Lilly and Company 4.9% 15-OCT-2035
Yield to maturity
Maturity date
Oct 15, 2035
LLY6003479
Eli Lilly and Company 4.9% 12-FEB-2032
Yield to maturity
Maturity date
Feb 12, 2032

See all LLYD bonds